NTRA:NGS-Natera Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 161.21

Change

+4.05 (+2.58)%

Market Cap

USD 0.67B

Volume

1.44M
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Natera Inc is a diagnostics company with proprietary molecular and bioinformatics technology that it is deploying to change the management of genetic disease.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-28 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 37.95B
ILMN Illumina Inc

N/A

USD 11.99B
ICLR ICON PLC

N/A

USD 11.79B
EXAS EXACT Sciences Corporation

N/A

USD 10.87B
MEDP Medpace Holdings Inc

N/A

USD 8.65B
GH Guardant Health Inc

N/A

USD 5.04B
RDNT RadNet Inc

N/A

USD 4.31B
SHC Sotera Health Co

N/A

USD 3.45B
VCYT Veracyte Inc

N/A

USD 2.51B
WGS GeneDx Holdings Corp.

N/A

USD 1.95B

ETFs Containing NTRA

GNOG:LSE Global X Genomics & Biote.. 6.68 % 0.00 %

N/A

USD 8.06M
GNOM:SW 6.68 % 0.00 %

N/A

N/A
ARCG:LSE ARK Genomic Revolution UC.. 6.27 % 0.00 %

N/A

USD 8.76M
ARKG:LSE ARK Genomic Revolution UC.. 6.27 % 0.00 %

N/A

USD 8.76M
CURG:LSE VanEck Genomics and Healt.. 6.16 % 0.00 %

N/A

USD 4.76M
GN0M:XETRA Global X Genomics & Biote.. 6.12 % 0.00 %

N/A

USD 7.05M
BBH VanEck Biotech ETF 5.36 % 0.35 %

N/A

USD 0.34B
CURE:XETRA VanEck Genomics and Healt.. 4.55 % 0.00 %

N/A

N/A
EKG First Trust Nasdaq Lux Di.. 4.14 % 0.00 %

N/A

USD 3.28M
AWEG The Alger ETF Trust 3.39 % 0.00 %

N/A

USD 4.80M
CURE:AU ETFS S&P Biotech ETF 2.77 % 0.00 %

N/A

USD 0.04B
CNAV Mohr Company Nav ETF 2.68 % 0.00 %

N/A

USD 0.03B
WDNA WisdomTree BioRevolution .. 2.43 % 0.00 %

N/A

USD 1.98M
WBIO:LSE WisdomTree BioRevolution .. 2.43 % 0.00 %

N/A

USD 3.68M
WRNA:XETRA WisdomTree BioRevolution .. 2.39 % 0.00 %

N/A

USD 2.77M
IBB iShares Biotechnology ETF 2.34 % 0.47 %

N/A

USD 5.11B
WDNA:LSE WisdomTree BioRevolution .. 2.31 % 0.00 %

N/A

N/A
DOCG:LSE L&G Healthcare Breakthrou.. 2.24 % 0.00 %

N/A

USD 0.06B
DOCT:LSE L&G Healthcare Breakthrou.. 2.24 % 0.00 %

N/A

USD 0.06B
DOCT:SW L&G Healthcare Breakthrou.. 2.21 % 0.00 %

N/A

USD 0.06B
HEAL:SW iShares Healthcare Innova.. 2.18 % 0.00 %

N/A

USD 1.05B
XMLH:F Legal & General Ucits Etf.. 1.80 % 0.00 %

N/A

N/A
EQJS:LSE Invesco NASDAQ Next Gener.. 1.37 % 0.00 %

N/A

USD 0.04B
VBK Vanguard Small-Cap Growth.. 0.79 % 0.07 %

N/A

USD 17.83B
ARKG ARK Genomic Revolution ET.. 0.00 % 0.75 %

N/A

USD 0.89B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

N/A

USD 0.54B
BTEC 0.00 % 0.42 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

N/A

USD 0.04B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

N/A

USD 0.04B
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A
IS0R:F iShares High Yield Corpor.. 0.00 % 0.00 %

N/A

N/A
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.05B
IS0R:XETRA iShares $ High Yield Corp.. 0.00 % 0.00 %

N/A

N/A
IUSN:XETRA iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A
ZPRS:XETRA SPDR MSCI World Small Cap.. 0.00 % 0.00 %

N/A

N/A
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

N/A

N/A
BBMC JPMorgan BetaBuilders U.S.. 0.00 % 0.00 %

N/A

USD 1.77B
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.84% 73% C 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.84% 73% C 66% D+
Trailing 12 Months  
Capital Gain 46.79% 84% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.79% 84% B 86% B+
Trailing 5 Years  
Capital Gain 267.64% 100% F 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 267.64% 100% F 93% A
Average Annual (5 Year Horizon)  
Capital Gain 40.02% 84% B 87% B+
Dividend Return 40.02% 84% B 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 78.27% 36% F 24% F
Risk Adjusted Return 51.12% 93% A 80% B-
Market Capitalization 0.67B 97% N/A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 16.74 11% 8%
Price / Cash Flow Ratio 152.27 5% 1%
Price/Free Cash Flow Ratio -26.80 94% 96%
Management Effectiveness  
Return on Equity -19.42% 58% 43%
Return on Invested Capital -18.55% 56% 33%
Return on Assets -8.96% 52% 35%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.